MEK1 and AKT2 Mutations in Japanese Lung Cancer

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing Akihiko Miyanaga, MD, PhD, Mari Masuda, PhD, Koji.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.

A Hole in the Heart Journal of Thoracic Oncology

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD

ALK FISH and IHC: You Cannot Have One without the Other

EGFR and KRAS Mutations in Triple-Mutated Lung Cancer

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication

MET Mutation Associated with Responsiveness to Crizotinib

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Evaluation of Kras Gene Mutation and Copy Number in Thymic Carcinomas and Thymomas Hidefumi Sasaki, MD, PhD, Motoki Yano, MD, PhD, Yoshitaka Fujii, MD,

Germline Mutations in DNA Repair Genes in Lung Adenocarcinoma

Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation Vienna Ludovini, PhD,

Electronic Updates for JTO Readers

Hedgehog Signaling Pathway and Lung Cancer

A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK Satoshi Anai, MD, Masafumi.

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Frank Detterbeck, MD Journal of Thoracic Oncology

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients Jangchul Park, MD, Chiaki Kondo, MD, Junichi.

A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

A Hole in the Heart Journal of Thoracic Oncology

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

An Alternative Approach to Determining Therapeutic Choices in Advanced Non-small Cell Lung Carcinoma (NSCLC): Maximizing the Diagnostic Procedure and.

Erratum Journal of Thoracic Oncology

Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment Gerald S. Falchook, MD,

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Mitotic Inhibitors Journal of Thoracic Oncology

A Translational View of the Molecular Pathogenesis of Lung Cancer

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Daniel B. Costa, MD, PhD, Susumu Kobayashi, MD, PhD

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Pulmonary Metastasectomy in Breast Cancer

Phase I Study of Lenalidomide in Solid Tumors

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Rapid Detection of Hotspot Mutations in Epidermal Growth Factor Receptor by Polymerase Chain Reaction Facilitates the Management of Non-small Cell Lung.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Genetic Changes in Squamous Cell Lung Cancer: A Review

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Ethnic Differences in the Management of Lung Cancer in New Zealand

International Thymic Malignancies Interest Group: A Way Forward

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

European Lung Cancer Conference (ELCC) 2016 Organisation

S-1 Treatment for Chemorefractory Thymic Carcinoma

Regina M. Vidaver, PhD, Beth S. Schachter, PhD

IASLC 6th Latin American Conference on Lung Cancer

Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation Yao-Wen Kuo, MD, Shang-Gin Wu, MD, Chao-Chi.

Annemarie Becker, MD, PhD, Atie van Wijk, RN, Egbert F

Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Two Rare Exon 21 EGFR Mutations in Patients Treated with Gefitinib

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findings in Peripheral Pulmonary Adenocarcinoma Motoki Yano, MD, PhD, Hidefumi.

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

MEK1 and AKT2 Mutations in Japanese Lung Cancer Hidefumi Sasaki, MD, PhD, Yu Hikosaka, MD, Osamu Kawano, MD, Satoru Moriyama, MD, PhD, Motoki Yano, MD, PhD, Yoshitaka Fujii, MD, PhD Journal of Thoracic Oncology Volume 5, Issue 5, Pages 597-600 (May 2010) DOI: 10.1097/JTO.0b013e3181d35236 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 MEK1 gene mutation. One hundred seventy-one nucleotide change from G to T at exon 2, introduces a substitution of lysine (K) to asparagine (N) at amino acid position 57 (K57N) of the MEK1 protein. Journal of Thoracic Oncology 2010 5, 597-600DOI: (10.1097/JTO.0b013e3181d35236) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 AKT2 mutation at kinase domain, R371H, at exon 11. Left: forward sequence from lung cancer samples. Right: reverse sequence. Journal of Thoracic Oncology 2010 5, 597-600DOI: (10.1097/JTO.0b013e3181d35236) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions